Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 2/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5253438 | 0.95 | ROCK2 (0.61) | AGPAT2ROCK2HRH4ROCK1AURKB | |
| SCHEMBL10036314 | 0.90 | ROCK2 (0.52) | AGPAT2ROCK2HSP90AA1HSP90AB1ADORA2A | |
| SCHEMBL10036354 | 0.88 | ROCK2 (0.68) | AGPAT2ROCK2ROCK1AURKB | |
| SCHEMBL5256872 | 0.85 | ROCK2 (0.66) | AGPAT2ROCK2HRH4KDM4EHSP90AA1 | |
| SCHEMBL5253850 | 0.83 | POLA1 (0.57) | AGPAT2ROCK2MAPTAURKAPDPK1 | |
| SCHEMBL5256438 | 0.81 | ROCK2 (0.71) | AGPAT2ROCK2MAPTTGFBR1KMT2A | |
| SCHEMBL10036355 | 0.81 | ROCK2 (0.75) | AGPAT2ROCK2HRH4AURKAPDPK1 | |
| SCHEMBL10036306 | 0.80 | ROCK2 (0.72) | AGPAT2ROCK2MAPTAURKAPDPK1 | |
| SCHEMBL10036309 | 0.78 | ROCK2 (0.92) | AGPAT2ROCK2HRH4ADORA2AADORA1 | |
| SCHEMBL14340751 | 0.78 | POLA1 (0.53) | AGPAT2ROCK2MAPTAURKAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | claimed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | claimed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | claimed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | claimed |
| EP-1470121-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-10-27 | — | — | EP | claimed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | claimed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | claimed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | AGPAT2 3201/4885ROCK2 3/4885HRH4 4153/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | AGPAT2 3057/4885ROCK2 5/4885HRH4 4574/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | AGPAT2 3201/4885ROCK2 3/4885HRH4 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.